

ForPatients

by Roche

Relapsed or Refractory Multiple Myeloma

A Study to Evaluate RO7851624 in Participants With Relapsed/ Refractory Multiple Myeloma (RRMM)

Trial Status
Not Yet Recruiting

Trial Runs In
0 Countries

Trial Identifier
NCT07558915 GO46140

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This study will evaluate safety, pharmacokinetics (PK), clinical activity and pharmacodynamics (PD) of RO7851624 in participants with RRMM who are triple-class exposed (treated with proteasome inhibitors [PIs], immunomodulators [IMiDs], and anti-cluster of differentiation 38 [anti-CD38] monoclonal antibodies), and have limited remaining standard treatment options due to refractoriness, intolerance, or multiple prior therapies.

Genentech, Inc.
Sponsor

Phase 1
Phase

NCT07558915 GO46140
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years

Healthy Volunteers
No
